274 related articles for article (PubMed ID: 31623615)
21. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
[TBL] [Abstract][Full Text] [Related]
22. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
[TBL] [Abstract][Full Text] [Related]
23. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
Topkan E; Bolukbasi Y; Ozdemir Y; Besen AA; Mertsoylu H; Selek U
J Geriatr Oncol; 2019 Jul; 10(4):567-572. PubMed ID: 31178158
[TBL] [Abstract][Full Text] [Related]
25. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Yang YJ; Park JC; Kim HK; Kang JH; Park SY
Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
[TBL] [Abstract][Full Text] [Related]
26. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.
Sher DJ; Gielda BT; Liptay MJ; Warren WH; Batus M; Fidler MJ; Garg S; Bonomi P
Clin Lung Cancer; 2013 Jul; 14(4):370-5. PubMed ID: 23260389
[TBL] [Abstract][Full Text] [Related]
28. The prognostic role of circulating CD8
An N; Wang H; Jia W; Jing W; Liu C; Zhu H; Yu J
J Transl Med; 2019 Dec; 17(1):402. PubMed ID: 31796037
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of a prognostic scoring system based on the systemic inflammatory and nutritional status of patients with locally advanced non-small-cell lung cancer treated with chemoradiotherapy.
Mitsuyoshi T; Matsuo Y; Itou H; Shintani T; Iizuka Y; Kim YH; Mizowaki T
J Radiat Res; 2018 Jan; 59(1):50-57. PubMed ID: 29182777
[TBL] [Abstract][Full Text] [Related]
30. CD8
Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
[TBL] [Abstract][Full Text] [Related]
31. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers.
Wakabayashi O; Yamazaki K; Oizumi S; Hommura F; Kinoshita I; Ogura S; Dosaka-Akita H; Nishimura M
Cancer Sci; 2003 Nov; 94(11):1003-9. PubMed ID: 14611679
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of peripheral blood T lymphocyte surface activation markers and transcription factors in patients with early stage non-small cell lung cancer.
Rutkowski J; Cyman M; Ślebioda T; Bemben K; Rutkowska A; Gruchała M; Kmieć Z; Pliszka A; Zaucha R
Cell Immunol; 2017 Dec; 322():26-33. PubMed ID: 28939130
[TBL] [Abstract][Full Text] [Related]
33. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
Talebian Yazdi M; van Riet S; van Schadewijk A; Fiocco M; van Hall T; Taube C; Hiemstra PS; van der Burg SH
Oncotarget; 2016 Jan; 7(3):3477-88. PubMed ID: 26658106
[TBL] [Abstract][Full Text] [Related]
34. Variation of blood T lymphocyte subgroups in patients with non- small cell lung cancer.
Wang WJ; Tao Z; Gu W; Sun LH
Asian Pac J Cancer Prev; 2013; 14(8):4671-3. PubMed ID: 24083723
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of peripheral naive CD8
Zhao X; Zhang Y; Gao Z; Han Y
Future Oncol; 2022 Jan; 18(1):55-65. PubMed ID: 34608815
[No Abstract] [Full Text] [Related]
36. ADA/CD26 axis increases intra-tumor PD-1
Franzese O; Palermo B; Frisullo G; Panetta M; Campo G; D'Andrea D; Sperduti I; Taje R; Visca P; Nisticò P
Oncoimmunology; 2024; 13(1):2371051. PubMed ID: 38915783
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
38. Smoking history influences the prognostic value of peripheral naïve CD4+ T cells in advanced non-small cell lung cancer.
Liu C; Xu B; Li Q; Li A; Li L; Yue J; Hu Q; Yu J
Cancer Cell Int; 2019; 19():176. PubMed ID: 31320838
[TBL] [Abstract][Full Text] [Related]
39. Elevated level of peripheral CD8(+)CD28(-) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy.
Song G; Wang X; Jia J; Yuan Y; Wan F; Zhou X; Yang H; Ren J; Gu J; Lyerly HK
Cancer Immunol Immunother; 2013 Jun; 62(6):1123-30. PubMed ID: 23604172
[TBL] [Abstract][Full Text] [Related]
40. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
